Agreement of the Point of Care Test (POCT) Boditech iCHROMA™ COVID-19 IgG Antibody Assay with the Abbott Architect SARS-CoV-2 IgG Antibody Assay: An Advanced Study Approach | Chapter 05 | Issues and Developments in Medicine and Medical Research Vol. 3

 Background: While molecular tests are not ideal for public health screening, antibody testing are. The more portable the test, the better. A Covid-19 antibody test is included in the Boditech iCHROMATM point-of-care immunoassay analyser for the qualitative detection of IgG/IgM antibodies in human whole blood/serum/plasma. It is useful as a screening tool for detecting Covid-19 infection in early mild asymptomatic or acute patients with great sensitivity.

The goal of this study was to see how well the Boditech iCHROMATM Covid-19 antibody assay and the Abbott Architect SARS-CoV-2 IgG assay performed in terms of detecting IgG antibodies to SARS-CoV-2 in human serum and plasma.

Results: Of the 50 plasma samples tested, the Abbott Architect SARS-CoV-2 IgG assay and the Boditech iCHROMATM Covid-19 IgG antibody assay both indicated 20 (40%) of the plasma samples as positive. The Abbott Architect SARS-CoV-2 IgG antibody assay reported the remaining 30 (60 percent) plasma samples as negative. Only 27 of the 30 samples (90 percent) were found to be negative by the Boditech iCHROMATM Covid-19 IgG antibody assay.

Conclusion: The Boditech iCHROMATM Covid-19 IgG antibody assay and the Abbott Architect SARS-CoV-2 IgG assay have a 95 percent overall agreement, with a sensitivity of 100 percent and a specificity of 90 percent.

Author(S) Details

M. Bass
Laboratory of PathDirect, New Malden, UK.

J. Bolodeoku
Laboratory of PathDirect, New Malden, UK.

E. Stevenson
Laboratory of London Medical, UK.

C. Anyaeche
Pathaway Services Limited, Kettering, UK.

T. K. Kim
Boditech Med Inc, Korea.

V. Retnasingham
Laboratory of PathDirect, New Malden, UK.

View Book:- https://stm.bookpi.org/IDMMR-V3/article/view/5466